Charles Schwab
CGTX icon

Charles Schwab’s Cognition Therapeutics CGTX Stock Holding History

Charles Schwab’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$64.5K Hold
84,940
– – ﹤0.01% 3412
2025
Q4 		$115K Hold
84,940
– – ﹤0.01% 3391
2025
Q3 		$115K Buy
+84,940
New +$116K ﹤0.01% 3385
2024
Q3 		– Sell
-11,965
Closed -$19.9K – 3516
2024
Q2 		$19.9K Hold
11,965
– – ﹤0.01% 3589
2024
Q1 		$21.8K Hold
11,965
– – ﹤0.01% 3433
2023
Q4 		$22.1K Hold
11,965
– – ﹤0.01% 3474
2023
Q3 		$17.2K Hold
11,965
– – ﹤0.01% 3529
2023
Q2 		$21.9K Buy
+11,965
New +$25.3K ﹤0.01% 3548

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Charles Schwab's CGTX Position: Q1 2026 in Review

Charles Schwab held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 84,940 shares worth $64.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3412.

Charles Schwab first reported a position in CGTX in Q2 2023 and has held it in 8 quarters since. The position peaked at $115K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Charles Schwab held 84,940 shares of Cognition Therapeutics worth $64.5K as of Q1 2026.
  • Charles Schwab left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3412 holding.
  • Charles Schwab first reported a position in Cognition Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • Charles Schwab's Cognition Therapeutics position peaked at $115K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.